Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028)...
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2016-11, Vol.16 (11), p.610-615 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 615 |
|---|---|
| container_issue | 11 |
| container_start_page | 610 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 16 |
| creator | Bila, Jelena Sretenovic, Aleksandra Jelicic, Jelena Tosic, Natasa Glumac, Irena Fekete, Marija Dencic Antic, Darko Balint, Milena Todorovic Markovic, Olivera Milojevic, Zoran Radojkovic, Milica Trajkovic, Goran Puric, Mila Pavlovic, Sonja Mihaljevic, Biljana |
| description | Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression-free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach.
To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT).
The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively.
A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012).
CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach. |
| doi_str_mv | 10.1016/j.clml.2016.08.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1839133349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2152265016303810</els_id><sourcerecordid>1839133349</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-df2c364b8ab6870853f41a2dfeb77f89c8c26efbed38e0d7aa8b9205574ce51b3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMoPqp_wIXM0k3HPDqZDLiRUh_QYkHFZchkbmpKZlKTqdh_b0q1S1f3LL5z4H4IXRKcE0z4zTLXrnU5TTnHIse4PECnlBR0SDmvDve5wCfoLMZlAjAm1TE6oSUngnF8iubz4Bedj73V2YtddNZYrToNmTfZGALUznfZ5HsVIEabou2yueotdH3M3m3_kc3WrrcrB9lsA8636hwdGeUiXPzeAXq7n7yOH4fT54en8d10qFnB-2FjqGZ8VAtVc1FiUTAzIoo2BuqyNKLSQlMOpoaGCcBNqZSoK4qLohxpKEjNBuh6t7sK_nMNsZetjRqcUx34dZTpv4owxkZVQukO1cHHGMDIVbCtChtJsNyalEu5NSm3JiUWMolKpavf_XXdQrOv_KlLwO0OgPTll4Ugo05eNDQ2gO5l4-1_-z9gR4WZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1839133349</pqid></control><display><type>article</type><title>Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bila, Jelena ; Sretenovic, Aleksandra ; Jelicic, Jelena ; Tosic, Natasa ; Glumac, Irena ; Fekete, Marija Dencic ; Antic, Darko ; Balint, Milena Todorovic ; Markovic, Olivera ; Milojevic, Zoran ; Radojkovic, Milica ; Trajkovic, Goran ; Puric, Mila ; Pavlovic, Sonja ; Mihaljevic, Biljana</creator><creatorcontrib>Bila, Jelena ; Sretenovic, Aleksandra ; Jelicic, Jelena ; Tosic, Natasa ; Glumac, Irena ; Fekete, Marija Dencic ; Antic, Darko ; Balint, Milena Todorovic ; Markovic, Olivera ; Milojevic, Zoran ; Radojkovic, Milica ; Trajkovic, Goran ; Puric, Mila ; Pavlovic, Sonja ; Mihaljevic, Biljana</creatorcontrib><description>Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression-free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach.
To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT).
The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively.
A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012).
CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2016.08.007</identifier><identifier>PMID: 27618360</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; CRBN expression ; Female ; Gene Expression ; Humans ; Immunomodulatory drugs ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - diagnosis ; Multiple Myeloma - genetics ; Multiple Myeloma - mortality ; Multiple Myeloma - therapy ; Neoplasm Staging ; Peptide Hydrolases - genetics ; Prognosis ; Treatment ; Treatment Outcome</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2016-11, Vol.16 (11), p.610-615</ispartof><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-df2c364b8ab6870853f41a2dfeb77f89c8c26efbed38e0d7aa8b9205574ce51b3</citedby><cites>FETCH-LOGICAL-c356t-df2c364b8ab6870853f41a2dfeb77f89c8c26efbed38e0d7aa8b9205574ce51b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2152265016303810$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27618360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bila, Jelena</creatorcontrib><creatorcontrib>Sretenovic, Aleksandra</creatorcontrib><creatorcontrib>Jelicic, Jelena</creatorcontrib><creatorcontrib>Tosic, Natasa</creatorcontrib><creatorcontrib>Glumac, Irena</creatorcontrib><creatorcontrib>Fekete, Marija Dencic</creatorcontrib><creatorcontrib>Antic, Darko</creatorcontrib><creatorcontrib>Balint, Milena Todorovic</creatorcontrib><creatorcontrib>Markovic, Olivera</creatorcontrib><creatorcontrib>Milojevic, Zoran</creatorcontrib><creatorcontrib>Radojkovic, Milica</creatorcontrib><creatorcontrib>Trajkovic, Goran</creatorcontrib><creatorcontrib>Puric, Mila</creatorcontrib><creatorcontrib>Pavlovic, Sonja</creatorcontrib><creatorcontrib>Mihaljevic, Biljana</creatorcontrib><title>Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression-free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach.
To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT).
The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively.
A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012).
CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>CRBN expression</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Immunomodulatory drugs</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - mortality</subject><subject>Multiple Myeloma - therapy</subject><subject>Neoplasm Staging</subject><subject>Peptide Hydrolases - genetics</subject><subject>Prognosis</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMoPqp_wIXM0k3HPDqZDLiRUh_QYkHFZchkbmpKZlKTqdh_b0q1S1f3LL5z4H4IXRKcE0z4zTLXrnU5TTnHIse4PECnlBR0SDmvDve5wCfoLMZlAjAm1TE6oSUngnF8iubz4Bedj73V2YtddNZYrToNmTfZGALUznfZ5HsVIEabou2yueotdH3M3m3_kc3WrrcrB9lsA8636hwdGeUiXPzeAXq7n7yOH4fT54en8d10qFnB-2FjqGZ8VAtVc1FiUTAzIoo2BuqyNKLSQlMOpoaGCcBNqZSoK4qLohxpKEjNBuh6t7sK_nMNsZetjRqcUx34dZTpv4owxkZVQukO1cHHGMDIVbCtChtJsNyalEu5NSm3JiUWMolKpavf_XXdQrOv_KlLwO0OgPTll4Ugo05eNDQ2gO5l4-1_-z9gR4WZ</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Bila, Jelena</creator><creator>Sretenovic, Aleksandra</creator><creator>Jelicic, Jelena</creator><creator>Tosic, Natasa</creator><creator>Glumac, Irena</creator><creator>Fekete, Marija Dencic</creator><creator>Antic, Darko</creator><creator>Balint, Milena Todorovic</creator><creator>Markovic, Olivera</creator><creator>Milojevic, Zoran</creator><creator>Radojkovic, Milica</creator><creator>Trajkovic, Goran</creator><creator>Puric, Mila</creator><creator>Pavlovic, Sonja</creator><creator>Mihaljevic, Biljana</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201611</creationdate><title>Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma</title><author>Bila, Jelena ; Sretenovic, Aleksandra ; Jelicic, Jelena ; Tosic, Natasa ; Glumac, Irena ; Fekete, Marija Dencic ; Antic, Darko ; Balint, Milena Todorovic ; Markovic, Olivera ; Milojevic, Zoran ; Radojkovic, Milica ; Trajkovic, Goran ; Puric, Mila ; Pavlovic, Sonja ; Mihaljevic, Biljana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-df2c364b8ab6870853f41a2dfeb77f89c8c26efbed38e0d7aa8b9205574ce51b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>CRBN expression</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Immunomodulatory drugs</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - mortality</topic><topic>Multiple Myeloma - therapy</topic><topic>Neoplasm Staging</topic><topic>Peptide Hydrolases - genetics</topic><topic>Prognosis</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bila, Jelena</creatorcontrib><creatorcontrib>Sretenovic, Aleksandra</creatorcontrib><creatorcontrib>Jelicic, Jelena</creatorcontrib><creatorcontrib>Tosic, Natasa</creatorcontrib><creatorcontrib>Glumac, Irena</creatorcontrib><creatorcontrib>Fekete, Marija Dencic</creatorcontrib><creatorcontrib>Antic, Darko</creatorcontrib><creatorcontrib>Balint, Milena Todorovic</creatorcontrib><creatorcontrib>Markovic, Olivera</creatorcontrib><creatorcontrib>Milojevic, Zoran</creatorcontrib><creatorcontrib>Radojkovic, Milica</creatorcontrib><creatorcontrib>Trajkovic, Goran</creatorcontrib><creatorcontrib>Puric, Mila</creatorcontrib><creatorcontrib>Pavlovic, Sonja</creatorcontrib><creatorcontrib>Mihaljevic, Biljana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bila, Jelena</au><au>Sretenovic, Aleksandra</au><au>Jelicic, Jelena</au><au>Tosic, Natasa</au><au>Glumac, Irena</au><au>Fekete, Marija Dencic</au><au>Antic, Darko</au><au>Balint, Milena Todorovic</au><au>Markovic, Olivera</au><au>Milojevic, Zoran</au><au>Radojkovic, Milica</au><au>Trajkovic, Goran</au><au>Puric, Mila</au><au>Pavlovic, Sonja</au><au>Mihaljevic, Biljana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2016-11</date><risdate>2016</risdate><volume>16</volume><issue>11</issue><spage>610</spage><epage>615</epage><pages>610-615</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression-free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach.
To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT).
The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively.
A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012).
CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27618360</pmid><doi>10.1016/j.clml.2016.08.007</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2016-11, Vol.16 (11), p.610-615 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1839133349 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use CRBN expression Female Gene Expression Humans Immunomodulatory drugs Kaplan-Meier Estimate Male Middle Aged Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - genetics Multiple Myeloma - mortality Multiple Myeloma - therapy Neoplasm Staging Peptide Hydrolases - genetics Prognosis Treatment Treatment Outcome |
| title | Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A24%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Significance%20of%20Cereblon%20Expression%20in%20Patients%20With%20Multiple%20Myeloma&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Bila,%20Jelena&rft.date=2016-11&rft.volume=16&rft.issue=11&rft.spage=610&rft.epage=615&rft.pages=610-615&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2016.08.007&rft_dat=%3Cproquest_cross%3E1839133349%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1839133349&rft_id=info:pmid/27618360&rft_els_id=S2152265016303810&rfr_iscdi=true |